J Clin Oncol: The combined ovarian inhibition of tymoxifen significantly prolongs the disease-free survival of patients with pre menoporal breast cancer

In pre-menoporary breast cancer patients who completed chemotherapy, ovarian function inhibition (OFS) was added to his tam therapy for 5 years, extending the patient's disease-free survival (DFS).
study evaluated the efficacy of adding 2 years of OFS to hormone-positive breast cancer patients after chemotherapy to remain pre-menoporary or restore ovarian function, the results of which were published online in J Clin Oncol.
study selected 1,483 pre-menoanthor women (age ≤45) and estrogen-positive breast cancer underwent explicit surgical treatment after completing complementary or new complementary chemotherapy.
2 years after entering the group, ovarian function was assessed every 6 months based on follicle irritant levels and a history of vaginal bleeding.
If the ovary function is confirmed to be pre-menoptosis at each visit, patients are randomly assigned to the 5-year TAM-only group or the 5-year TAM plus 2 year OFS group to take the GOsherin (TAM-OFS) group monthly.
DFS defines the time from the time of registration to the time the first event occurs.
results were included in 1,293 patients, and eventually 1,282 patients were eligible for analysis.
the estimated five-year DFS rate of 91.1% for the TAM-OFS group, and the estimated five-year DFS rate for the TAM group alone was 87.5% (HR, 0.69; 95% CI, 0.48 to 0.97; P=0.033).
tam and OFS group estimated the total five-year survival rate at 99.4%, and the TAM-only group at 97.8% (HR, 0.31; 95% CI, 0.10 to 0.94; P . . . 029).
, the results showed that for patients who were still in the pre-menopian or ovarian function recovery period after chemotherapy, the addition of 2 years of OFS on top of TAM significantly improved DFS compared to simply TAM.
。